Aripiprazole LA-Ziprasidone

From Psychiatrienet
Revision as of 11:56, 17 March 2015 by InvoerWalter (talk | contribs) (Created page with '{{Drugswitch | from = Aripiprazole LA | to = Ziprasidone | stop = {{Lastinjection}} | start = {{Startslweeks}} | info = {{caveQT}}{{SPCaripiprazoleLA}} | view = StopDepotStartOr...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Aripiprazole
long acting
Type Antipsychotic
Group Atypical AP
Other use moodstabilizer
links
Medscape Aripiprazole
EMEA abilify
PubChem 60975
PubMed Aripiprazole
Kompas (Dutch) Aripiprazole
Wikipedia Aripiprazole
Ziprasidone
Type Antipsychotic
Group Atypical AP
Other use Moodstabilizer
links
Medscape Ziprasidone
PubChem 60854
PubMed Ziprasidone
Wikipedia Ziprasidone

Switch medication from Aripiprazole LA to Ziprasidone.

Nietinrijdenbord.png Stop Aripiprazole LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Ziprasidone
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[1]
  • More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [2]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Aripiprazole LA
Eenrichtingbord.png — Ziprasidone


  1. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
  2. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.